CIK-CAR immunotherapy - Formula Pharmaceuticals

Drug Profile

CIK-CAR immunotherapy - Formula Pharmaceuticals

Alternative Names: C.I.K.-CAR.CD19

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Milan Bicocca
  • Developer Fondazione Matilde Tettamanti; Formula Pharmaceutical
  • Class Antineoplastics; Cell therapies
  • Mechanism of Action CD19 antigen inhibitors; Cytokine induced killer cell stimulants; Cytotoxic T lymphocyte stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Acute lymphoblastic leukaemia
  • Preclinical Non-Hodgkin's lymphoma

Most Recent Events

  • 18 Sep 2017 Phase-I/II clinical trials in Acute lymphoblastic leukaemia (Second-line therapy or greater, In children, In adults) in Italy (Parenteral)
  • 11 May 2015 Preclinical trials in Non-Hodgkin's lymphoma in Italy (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top